Malou Janssen

Malou Janssen

Auto-generated profile, based on publicly available information

Malou Janssen

Department of Respiratory Medicine Erasmus Medical Center Rotterdam The Netherlands

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2015 in Manual Therapy
Verified
Journal Article
Closed access
JVJ. de Vries
J. de Vries
BIB.K. Ischebeck
B.K. Ischebeck
LVLennard Voogt
Lennard Voogt
JGJ.N. van der Geest
J.N. van der Geest
MJM. Janssen
M. Janssen
GKG.J. Kleinrensink
G.J. Kleinrensink

22 May 2021 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
MJMalou Janssen
Malou Janssen
JMJ. Han. J. Meeder
J. Han. J. Meeder
LSLeonard Seghers
Leonard Seghers
CUCorstiaan Den Uil
Corstiaan Den Uil
Background: Acute respiratory distress syndrome (ARDS) often requires controlled ventilation, yielding high mechanical power and possibly further injury. Veno-venous extracorporeal membrane oxygenation (VV-ECMO) can be used as a bridge to recovery, however, if this fails the end result is destroyed lung parenchyma. This condition is fatal and the only remaining alternative is lung transplantation. In the case study presented in this paper, lung transplantation was not an option given the critically ill state and the presence of HLA antibodies. Airway pressure release ventilation (APRV) may be valuable in ARDS, but APRV settings recommended in various patient and clinical studies are inconsistent. The Time Controlled Adaptive Ventilation (TCAV™) method is the most studied technique to set and adjust the APRV mode and uses an extended continuous positive airway pressure (CPAP) Phase in combination with a very brief Release Phase. In addition, the TCAV™ method settings are personalized and adaptive based on changes in lung pathophysiology. We used the TCAV™ method in a case of severe ARDS, which enabled us to open, stabilize and slowly heal the severely damaged lung parenchyma. Case presentation: A 43-year-old woman presented with Staphylococcus Aureus necrotizing pneumonia. Progressive respiratory failure necessitated invasive mechanical ventilation and VV-ECMO. Mechanical ventilation (MV) was ultimately discontinued because lung protective settings resulted in trivial tidal volumes. She was referred to our academic transplant center for bilateral lung transplantation after the remaining infection had been cleared. We initiated the TCAV™ method in order to stabilize the lung parenchyma and to promote tissue recovery. This strategy was challenged by the presence of a large bronchopleural fistula, however, APRV enabled weaning from VV-ECMO and mechanical ventilation. After two months, following nearly complete surgical closure of the remaining bronchopleural fistulas, the patient was readmitted to ICU where she had early postoperative complications. Since other ventilation modes resulted in significant atelectasis and hypercapnia, APRV was restarted. The patient was then again weaned from MV. Conclusions: The TCAV™ method can be useful to wean challenging patients with severe ARDS and might contribute to lung recovery. In this particular case, a lung transplantation was circumvented.

21 October 2016 in BMC Musculoskeletal Disorders
Verified
Journal Article
Open access
PDF file
BIBritta Kristina Ischebeck
Britta Kristina Ischebeck
JVJurryt de Vries
Jurryt de Vries
JGJos N Van der Geest
Jos N Van der Geest
MJMalou Janssen
Malou Janssen
JWJan Paul Van Wingerden
Jan Paul Van Wingerden
MFMaarten A Frens
Maarten A Frens
Many people with Whiplash Associated Disorders (WAD) report problems with vision, some of which may be due to impaired eye movements. Better understanding of such impaired eye movements could improve diagnostics and treatment strategies. This systematic review surveys the current evidence on changes in eye movements of patients with WAD and explains how the oculomotor system is tested. Nine electronic data bases were searched for relevant articles from inception until September 2015. All studies which investigated eye movements in patients with WAD and included a healthy control group were screened for inclusion. Qualifying studies were retrieved and independently assessed for methodological quality using the Methodology Checklists provided by the Scottish Intercollegiate Guidelines Network. Fourteen studies out of 833 unique hits were included. Ten studies reported impaired eye movements in patients with WAD and in four studies no differences compared to healthy controls were found. Different methods of eye movement examination were used in the ten studies: in five studies, the smooth pursuit neck torsion test was positive, in two more the velocity and stability of head movements during eye-coordination tasks were decreased, and in another three studies the cervico-ocular reflex was elevated. Overall the reviewed studies show deficits in eye movement in patients with WAD, but studies and results are varied. When comparing the results of the 14 relevant publications, one should realise that there are significant differences in test set-up and patient population. In the majority of studies patients show altered compensatory eye movements and smooth pursuit movements which may impair the coordination of head and eyes.

5 March 2021 in European Journal of Neurology
Verified
Journal Article
Open access
PDF file
MJMalou Janssen
Malou Janssen
FBFlip van Broekhoven
Flip van Broekhoven
PSPeter Sillevis Smitt
Peter Sillevis Smitt
MFMaarten Frens
Maarten Frens
JGJos van der Geest
Jos van der Geest
Background and purpose Paraneoplastic neurological syndromes with Hu‐antibodies (Hu‐PNS) are immune‐mediated disorders in patients with malignancies, most frequently small cell lung cancer, affecting both the peripheral and central nervous system (CNS). In Hu‐PNS, brainstem and cerebellar involvement are common. Here, we assessed whether eye‐movement disturbances can be used for diagnosis and monitoring of CNS involvement in Hu‐PNS. Methods Twenty‐nine patients with Hu‐PNS (17 females; mean age, 63.2 years,) and 14 healthy age‐matched controls (seven females; mean age, 60.2 years) were included. Saccadic and smooth pursuit eye movements in response to visual stimuli were recorded with video‐oculography. Eye movements were scored quantitatively (number of correction saccades, saccadic intrusions, and saccades during fixation period) and qualitatively by two eye‐movement experts. In 20 patients, up to three follow‐up measurements were made during subsequent hospital visits with fixed 4‐week intervals. Disease course was assessed using the modified Rankin Scale. Results Eye movements were disturbed in 26 of 29 Hu‐PNS patients, with horizontal eye movements being in general more impaired. Moreover, in 12 of the 14 Hu‐PNS patients without clinical CNS involvement, eye movements were disturbed. Changes in eye‐movement control over a period of up to 12 weeks were significantly correlated with the clinical response to treatment (ρ = 0.52, p = 0.02). Conclusions Hu‐PNS often affects eye‐movement control, also in the absence of CNS signs or symptoms. Eye‐movement recordings in Hu‐PNS patients might be a useful tool to objectively monitor progression and treatment efficacy in Hu‐PNS patients.

16 March 2026 in Critical Care Explorations
Verified
Journal Article
Open access
DFDaan F.L. Filippini
Daan F.L. Filippini
JKJessica Khyali
Jessica Khyali
MJMalou Janssen
Malou Janssen
EREmma Rademaker
Emma Rademaker
OCOlaf L Cremer
Olaf L Cremer
AGAmsterdam UMC COVID-19 Biobank Study Group
Amsterdam UMC COVID-19 Biobank Study Group
OBJECTIVES: This study evaluated whether the established efficacy of tocilizumab, an interleukin-6 (IL-6) receptor antagonist, differs between the hypoinflammatory and hyperinflammatory subphenotypes. DESIGN: Retrospective analysis of data from three biobanks. SETTING: ICUs of three university teaching hospitals in the Netherlands. PATIENTS: Mechanically ventilated patients with COVID-19. INTERVENTIONS: Tocilizumab administration vs. no administration. MEASUREMENTS AND MAIN RESULTS: A total of 561 patients were included. Based on a classifier model incorporating IL-6, tumor necrosis factor receptor 1, and bicarbonate, 95% were classified as Hypoinflammatory and 5% as Hyperinflammatory. Tocilizumab was associated with a significant reduction in 30-day mortality in the overall cohort, even after adjustment for confounders ( p = 0.014). However, there was no evidence that treatment effectiveness differed between the two subphenotypes ( p = 0.59). CONCLUSIONS: In this cohort, tocilizumab significantly reduced 30-day mortality overall. Although the number of Hyperinflammatory patients was low, there was no evidence that its efficacy differed between inflammatory subphenotypes. These findings underscore the importance of including both subphenotypes in future trials evaluating the differential effects of tocilizumab.

26 March 2026 in Clinical Case Reports
Verified
Journal Article
Open access
MJMatthijs L. Janssen
Matthijs L. Janssen
PCP. P. Chandoesing
P. P. Chandoesing
MJM. Janssen
M. Janssen
Here, we demonstrate conservative treatment, using only antibiotics, oxygen, and analgesics, as a viable option for barotrauma‐induced tracheal laceration when a broncho‐esophageal fistula is not present.